Public Employees Retirement System of Ohio Acquires Shares of 55,503 Repligen Corporation $RGEN

Public Employees Retirement System of Ohio acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 55,503 shares of the biotechnology company's stock, valued at approximately $7,573,000. Public Employees Retirement System of Ohio owned about 0.10% of Repligen as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. ABS Investment Management LLC bought a new stake in shares of Repligen in the second quarter worth $191,016,000. Measured Wealth Private Client Group LLC bought a new position in shares of Repligen during the third quarter worth about $29,000. Los Angeles Capital Management LLC acquired a new position in Repligen in the fourth quarter worth about $36,000. Farther Finance Advisors LLC grew its position in shares of Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 128 shares in the last quarter. Finally, Itau Unibanco Holding S.A. increased its holdings in shares of Repligen by 38.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company's stock valued at $62,000 after acquiring an additional 104 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Jefferies Financial Group restated a "hold" rating and set a $142.00 price objective on shares of Repligen in a research note on Tuesday, May 5th. JPMorgan Chase & Co. raised their price target on shares of Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Evercore reaffirmed an "outperform" rating and issued a $160.00 price target on shares of Repligen in a report on Monday, July 6th. Zacks Research upgraded shares of Repligen from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 30th. Finally, Benchmark upgraded Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $166.43.

Insider Buying and Selling at Repligen

In related news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Repligen Trading Down 6.1%

Repligen stock opened at $170.02 on Wednesday. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $188.73. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $9.60 billion, a price-to-earnings ratio of 232.90, a PEG ratio of 3.30 and a beta of 1.04. The firm has a 50-day moving average price of $153.95 and a two-hundred day moving average price of $133.50.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million for the quarter, compared to analysts' expectations of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts expect that Repligen Corporation will post 2.06 earnings per share for the current year.

Repligen Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source